Johnson & Johnson (JNJ) Financial History
Review Johnson & Johnson annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2007 through FY2025.
Financials
16 fiscal years, FY2007 to FY2025
Insider trades
461 trades
Risk factor changes
13 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
Johnson & Johnson Financial Statements
History since FY2007. Annual, in US dollars. Source: 10-K XBRL data.
Johnson & Johnson Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
Johnson & Johnson Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
Johnson & Johnson Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
Johnson & Johnson Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
Johnson & Johnson Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2007 🔒 | FY2008 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2021 | FY2022 | FY2023Insiders net sold $54.6M | FY2024Insiders net sold $8.1M | FY2025Insiders net sold $11.5M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $82.6B | $78.7B | $85.2B | $88.8B | $94.2B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | -4.7% | +8.2% | +4.3% | +6.0% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $54.2B | $55.3B | $58.6B | $61.4B | $63.9B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | — | — | — | — |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $14.7B | $20.9B | $35.2B | $14.1B | $26.8B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $37.1B | $35.9B | $30.8B | $38.4B | $49.9B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $20.2B | $19.8B | $18.2B | $19.8B | $19.7B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 17.8% | 26.5% | 41.3% | 15.8% | 28.5% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $5.51 | $7.81 | $13.72 | $5.79 | $11.03 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 28.6× | 21.9× | 11.4× | 25.1× | 18.8× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | — | — | — | — |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $171.05 | $177.02 | $156.62 | $145.44 | $206.72 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $176.65 | $156.76 | $144.64 | $207.01 | $272.48 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $186.67 | $180.82 | $168.83 | $215.16 | $287.59 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $155.75 | $144.97 | $142.75 | $140.70 | $200.96 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | +3.3% | -11.3% | -7.7% | +43.1% | +31.6% |
Johnson & Johnson Insider Transactions
From Form 4 filings. Showing the latest 5 of 461 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-09-08 | 2026-09-10 | Daniel Pinto Director | Grant or award | 113.098 | $31K | — |
| 2026-09-08 | 2026-09-10 | Eugene Woods Director | Grant or award | 135.717 | $37K | — |
| 2026-09-08 | 2026-09-10 | Marillyn Hewson Director | Grant or award | 180.956 | $50K | — |
| 2026-09-02 | 2026-09-04 | Timothy Schmid Executive VP, WW Chair, MedTech | Option exercise (8 trades) | 134,388 | $4.9M | — |
| 2026-09-02 | 2026-09-04 | Timothy Schmid Executive VP, WW Chair, MedTech | Sold (2 trades) | 33,597 | $9.2M at ~$275 | — |
Johnson & Johnson Risk Factor Changes
Latest 10-K compared with the year before. 13 changes found.
To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data (including confident…
While certain of the announced tariffs have been delayed, the U.S.
Changes in tax laws or regulations in the U.S.
The Company is subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may have a material adverse affect on the Company’s financial cond…
The threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased…
controls, to address this risk.
The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and market value of shares of its common stock may be less than, equal to or greater than the market…
Following the planned separation, the price of shares of the Company's common stock may fluctuate significantly
The Company will incur significant expenses in connection with the planned separation.
The costs to complete the planned separation will be significant.
In October 2025, the Company announced its intention to separate the Company's Orthopaedics business.
The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results
Risks related to the planned separation of our Orthopaedics business
Johnson & Johnson SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Quarterly report (10-Q) | 2026-10-21 | Quarter ended Sep 27, 2026 | View document |
| Current report (8-K) | 2026-10-13 | Quarterly results | View document |
| Current report (8-K) | 2026-08-04 | Executive change | View document |
| Current report (8-K) | 2026-07-29 | Company update | View document |
| Current report (8-K) | 2026-07-28 | Company update | View document |
Johnson & Johnson financial metrics by year
Johnson & Johnson in the S&P 500 rankings
- #36 by revenue as of FY2025
- #10 by net income as of FY2025
- #51 by net profit margin as of FY2025
- #11 by free cash flow as of FY2025
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.
Compare Johnson & Johnson with similar companies
- JNJ vs ABBV AbbVie
- JNJ vs ABT Abbott Laboratories
- JNJ vs BMY Bristol Myers Squibb
- JNJ vs LLY Eli Lilly
- JNJ vs MRK Merck
- JNJ vs PFE Pfizer
- JNJ vs REGN Regeneron Pharmaceuticals
- JNJ vs VRTX Vertex Pharmaceuticals
- JNJ vs VTRS Viatris
- JNJ vs ZTS Zoetis